These KRAS G12D degrader programs represent important attempts to conquer “undruggable” targets, potentially providing more effective and durable treatment options for KRAS‐driven tumors with extremely poor prognosis like pancreatic cancer through complete elimination of mutant proteins rather than simple functional inhibition. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.